P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

August 2012

Features

Health Care Reform

Don’t Know Much About Health Insurance Exchanges

The Next Critical Step: Educating Consumers and Small Businesses

By the end of 2012, states must figure out how they will provide exchanges for citizens to buy health care insurance. Much work remains to be done, including removing information barriers, to make health care accessible to all citizens by 2014.
Miriam Reisman

The Changing Landscape of Treatment Options for Metastatic Castrate-Resistant Prostate Cancer

Challenges and Solutions for Physicians and Patients

Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.
Carole Alison Chrvala, PhD

Adherence to 5-Alpha Reductase Inhibitor Therapy for Benign Prostatic Hyperplasia

Clinical and Economic Outcomes

Men with benign prostatic hyperplasia who received 5-ARIs and persisted with therapy had significantly reduced risks of acute urinary retention, less need for prostate surgery, and lower medical costs.
Stephen Gruschkus, PhD, MPH; Sara Poston, PharmD; Michael Eaddy, PharmD, PhD; and Sham Chaudhari, MS, PharmB

Meeting Highlights

2012 American Society of Clinical Oncology and American Society of Hypertension (27th Annual Scientific Meeting and Exposition)

Selected ASCO topics include drugs for melanoma, gastrointestinal tumors, non–small cell lung cancer, and advanced breast cancer. ASH presentations cover ambulatory blood pressure in type-2 diabetes, triple therapy in obese patients, the effect of body mass on cardiovascular outcomes, and a novel glucagon-like peptide agonist for diabetes.
Walter Alexander

Departments

Medication Errors

Reducing the Risk of Deadly Mixups with Epidural and Intravenous Drugs

Mixups of epidural and intravenous drugs can be deadly.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Congress Passes Unambitious User Fee Reauthorization and Expansion

Act Omits Key Provisions Sought by Pharmacy Groups

The FDA’s PDUFA reauthorization bill passes but omits significant safety provisions.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Drug Forecast

Cabazitaxel (Jevtana)

A Novel Agent for Metastatic Castration-Resistant Prostate Cancer

Cabazitaxel (Jevtana) for metastatic castration-resistant prostate cancer
Ginah Nightingale, PharmD, BCOP; and Jae Ryu, PharmD, BCOP, BCPS